Diagnostics and sequencing platforms are continuing to push deeper into clinical workflows, with partnerships aimed at making whole-genome sequencing and AI-driven cancer analysis more “default” in care. Genomic Medicine Sweden and the Hartwig Medical Foundation announced a strategic partnership to implement whole-genome sequencing and precision oncology in routine cancer care, including default WGS for adults with acute leukemia and rollouts for selected solid tumors. Separately, Sophia Genetics and Memorial Sloan Kettering Cancer Center outlined a precision medicine hub combining Sophia’s DDM AI platform with MSK clinical data to accelerate translational research and support companion diagnostics and clinical algorithms. The MoU described dedicated infrastructure for biopharma partners, with financial terms not disclosed. Both moves emphasize operational execution—data harmonization, pipeline validation, and evidence generation—rather than standalone research deployments.